Personalized mRNA vaccines and targeted drug approvals treat pancreatic cancer, with clinical trials documenting sustained immune responses and long-term remissions years after initial treatments began.
Why Researchers Test mRNA Vaccines Against Pancreatic Tumors
Malignant tumors in the pancreas recur in up to 80 percent of patients even after surgery and chemotherapy. To combat this high recurrence rate, researchers at Memorial Sloan Kettering Cancer Center developed therapeutic mRNA vaccines tailored to the genetic profile of individual tumors, as reported by Pravda.
The process begins with a tumor biopsy. Genomic analysis and artificial intelligence identify specific mutations. Researchers then create a custom mRNA sequence designed to teach the patient’s immune system to recognize and attack abnormal proteins produced by the tumor.
How Donna Gustafson Survived Stage II Pancreatic Cancer
Donna Gustafson became the world’s first recipient of a personalized mRNA vaccine designed to treat pancreatic cancer seven years ago, according to AZPM.
Pancreatic cancer is a lethal disease that affects about 70,000 Americans annually. Diagnosed with Stage II pancreatic cancer, she received nine doses of the vaccine alongside surgery and chemotherapy as part of a small clinical trial involving 16 patients.
Surgeon and scientist Dr Vinod Balachandran led the trial at Memorial Sloan Kettering Cancer Center in New York City. Laboratory measurements of Gustafson’s immune cells showed a 10,000-fold increase
in immune cell reproduction that remained high and flat for years beyond her final shot, according to Balachandran.
Gustafson shows zero evidence of disease today at age 72.
I have had 100% quality of life; I am back to where I was prior,
Gustafson said.
Out of the 16 patients in that initial trial, the vaccine worked on half, and seven of those eight participants remain alive today. Her husband, Ed Gustafson, noted that the mRNA injections produced minimal or no side effects compared to standard chemotherapy.
What Phase 2 Trials Reveal About Camupepimut and KRAS Mutations
A Phase 2 clinical trial published in Nature Medicine investigated an experimental vaccine called camupepimut, or ELI-002 7P. Elicio Therapeutics developed the treatment, and scientists at the Mayo Clinic led the study.
The vaccine teaches T lymphocytes to recognize seven common mutations in the KRAS gene. These mutations are found in about 90 percent of pancreatic ductal adenocarcinomas. The trial evaluated 144 patients who had undergone surgery and chemotherapy and showed no visible signs of disease on imaging at the start.
Of the 90 participants who received the vaccine and could be assessed, 98.9 percent developed increased T-cell responses against mutated KRAS, as reported by ScienceAlert.
The T-cell response was more than nine times greater than baseline measurements in more than 80 percent of patients.
Historically, pancreatic cancer has been very difficult to treat with immunotherapy,
said Ben George, a medical oncologist at the Mayo Clinic and lead author of the study. What is encouraging is that we were able to generate a strong immune response against KRAS mutations in nearly every patient we evaluated.
How Daraxonrasib Changes Treatment for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration approved daraxonrasib for adults with metastatic pancreatic cancer who have already received treatment, according to UTMB Health.
Researchers are continuing to study whether RAS-targeted therapies and mRNA vaccines can be utilized earlier in the course of the disease to further reduce recurrence risks.